AdaptHealth price target lowered to $14 from $16 at Baird

Baird lowered the firm’s price target on AdaptHealth (AHCO) to $14 from $16 and keeps an Outperform rating on the shares. The firm said the company is delivering in most categories, with strong BS/CF improvement, and overall operational improvement, except for Diabetes. The company’s diabetes business is bad, and it is getting a major overhaul.